Alethia Young
Stock Analyst at Cantor Fitzgerald
(3.68)
# 747
Out of 4,876 analysts
141
Total ratings
54.46%
Success rate
30.71%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $7.95 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $16.08 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $521.00 | +63.15% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $0.41 | +4,335.68% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $2.17 | +2,664.98% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.69 | +234.57% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $4.15 | +719.28% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $126.08 | +159.36% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $2.32 | +1,193.10% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $8.43 | +6,637.84% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $441.30 | -36.32% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.65 | +119.18% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.04 | +9,323.08% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $277.13 | +6.45% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $110.67 | -22.29% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $36.72 | +30.72% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.24 | +314.36% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $33.47 | +115.12% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.29 | +287.60% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $68.37 | +46.26% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $172.14 | +16.77% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $49.84 | +70.55% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $8.64 | +270.37% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $17.11 | +1,168.26% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $22.47 | +113.62% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $10.91 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $322.83 | -52.30% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $55.17 | +110.26% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $3.33 | +3,083.18% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $9.56 | +192.89% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $216.13 | -62.06% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $284.27 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.02 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.95
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.08
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $521.00
Upside: +63.15%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.41
Upside: +4,335.68%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $2.17
Upside: +2,664.98%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.69
Upside: +234.57%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $4.15
Upside: +719.28%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $126.08
Upside: +159.36%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $2.32
Upside: +1,193.10%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $8.43
Upside: +6,637.84%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $441.30
Upside: -36.32%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $3.65
Upside: +119.18%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.04
Upside: +9,323.08%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $277.13
Upside: +6.45%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $110.67
Upside: -22.29%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $36.72
Upside: +30.72%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $7.24
Upside: +314.36%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $33.47
Upside: +115.12%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.29
Upside: +287.60%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $68.37
Upside: +46.26%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $172.14
Upside: +16.77%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $49.84
Upside: +70.55%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $8.64
Upside: +270.37%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $17.11
Upside: +1,168.26%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $22.47
Upside: +113.62%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $10.91
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $322.83
Upside: -52.30%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $55.17
Upside: +110.26%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $3.33
Upside: +3,083.18%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $9.56
Upside: +192.89%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $216.13
Upside: -62.06%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $284.27
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.02
Upside: -